Stock comparison
LeMaitre Vascular
Teva Pharmaceutical Industries Limited
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
LMAT
LeMaitre Vascular
Market cap
$2.23B
Sector
Healthcare
TEVA
Teva Pharmaceutical Industries Limited
Market cap
$39.67B
Sector
Healthcare
Overall winner
LeMaitre Vascular LMAT
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | LMAT | TEVA | Winner |
|---|---|---|---|
| Warren Buffett | 77B | 46D | LMAT |
| Benjamin Graham | 89A | 60D | LMAT |
| Philip Fisher | 81C | 59C | LMAT |
| Peter Lynch | 67B | 53C | LMAT |
| Joel Greenblatt | 56D | 49D | LMAT |
| Charlie Munger | 68D | 50D | LMAT |
| Terry Smith | 69D | 41D | LMAT |
Side-by-side metrics
| Metric | LMAT | TEVA |
|---|---|---|
| Market cap | $2.23B | $39.67B |
| P/E (TTM) | 37.1x | 25.4x |
| EV/EBIT | 36.6x | 24.8x |
| ROIC (TTM) | 9.43% | 11.49% |
| Gross margin | 72.39% | 51.98% |
| Net margin | 24.35% | 9.03% |
| Revenue CAGR 5y | 12.75% | 2.1% |
| EPS CAGR 5y | 19.04% | 34.13% |
| Debt / Equity | 0.5x | 2.1x |
| Dividend yield | 0.84% | 0.0% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
LMAT leads on
- Dividend yield0.84%vs 0.0%+100%
- Revenue CAGR 5y12.75%vs 2.1%+84%
- Debt / Equity0.5xvs 2.1x+77%
- Net margin24.35%vs 9.03%+63%
TEVA leads on
- Market cap$39.67Bvs $2.23B+94%
- EPS CAGR 5y34.13%vs 19.04%+44%
- EV/EBIT24.8xvs 36.6x+32%
- P/E (TTM)25.4xvs 37.1x+32%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.